Qualigen Therapeutics Inc Ordinary Shares QLGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if QLGN is a good fit for your portfolio.
News
-
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
-
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
-
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Trading Information
- Previous Close Price
- $0.30
- Day Range
- $0.29–0.32
- 52-Week Range
- $0.28–1.26
- Bid/Ask
- $0.29 / $0.30
- Market Cap
- $1.83 Mil
- Volume/Avg
- 9,247 / 69,048
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
- Website
- https://www.qlgntx.com
Valuation
|
Metric
|
QLGN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
QLGN
|
|---|---|
Quick Ratio | 0.10 |
Current Ratio | 0.28 |
Interest Coverage | −7.18 |
Quick Ratio
QLGN
Profitability
|
Metric
|
QLGN
|
|---|---|
Return on Assets (Normalized) | −107.23% |
Return on Equity (Normalized) | −562.17% |
Return on Invested Capital (Normalized) | −221.64% |
Return on Assets
QLGN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hfbxfmrrtx | Fcqk | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wvgwrgg | Lyrrw | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mdwmmnt | Rtkyh | $97.8 Bil | |
MRNA
| Moderna Inc | Tpxgqhz | Lyhp | $41.3 Bil | |
ARGX
| argenx SE ADR | Kvgwtkb | Rmts | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Wfnjwznxr | Jjjsp | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Pxknscc | Nwhfydt | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ftnpnqm | Clmmbs | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wkyhkvspwl | Sxqrxp | $12.5 Bil | |
INCY
| Incyte Corp | Kgdjldnxq | Hmwydr | $11.6 Bil |